Abstract 260P
Background
The standard of care for metastatic pancreatic cancer after Gemcitabine-based chemotherapy is liposomal irinotecan plus fluorouracil/leucovorin (nal-IRI/FL). In retrospective study, FOLFIRINOX also showed effective response and disease control compared with nal-IRI/FL. Although NALIRIFOX had also became a choice of front-line regimen of metastatic pancreatic cancer, the role of NALIRIFOX as subsequent treatment after Gemcitabine-based regimen is unknown.
Methods
We retrospectively reviewed the medical records of patients with metastatic pancreatic cancer who received NALIRIFOX as subsequent treatment after failure of Gemcitabine-based regimen at Taichung Veterans General Hospital (Taichung, Taiwan) between January 2023 and June 2024. The clinical characteristics and outcomes were analyzed.
Results
A total of 26 patients received NALIRIFOX after failure of Gemcitabine-based regimen were analyzed. 20 patients received NALIRIFOX as second-line treatment, and 6 patients received NALIRIFOX as third-line treatment (after Gemcitabine-based treatment and nal-IRI/FL). In patients received NALIRIFOX as second-line treatment, the response rate (RR) was 35% (7/20) and disease control rate was 65% (13/20). The progression-free survival (PFS) and overall survival (OS) were 5.0 months and 6.9 months, respectively. In patients received NALIRIFOX as third-line treatment, no patient response to NALIRIFOX, but DCR was 50% (3/6).
Conclusions
In our retrospective study, NALIRIFOX could be another choice for metastatic pancreatic cancer patients after failure of Gemcitabine-based treatment. The benefit was better as second-line regimen.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.